Huntington's disease therapeutic - Avergen Pharmaceuticals
Latest Information Update: 14 Jul 2016
At a glance
- Originator Avergen Pharmaceuticals
- Class Small molecules
- Mechanism of Action HD protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Huntington's disease
Most Recent Events
- 14 Jul 2016 Early research in Huntington's disease in Germany (PO)